Lewes, DE -- (SBWIRE) -- 07/25/2016 -- Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) pipeline Target constitutes close to 12 molecules. Out of which approximately 11 molecules are developed by Companies and remaining by the Universities/Institutes. Global Markets Direct's latest report Hepatocyte Growth Factor – Pipeline Review, H1 2016, outlays comprehensive information on the Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) Hepatocyte growth factor (HGF) is a paracrine cellular growth and morphogenic factor secreted by mesenchymal cells and stimulates epithelial cell proliferation, motility, morphogenesis and angiogenesis in various organs via tyrosine phosphorylation of its receptor. It has a major role in embryonic organ development, specifically in myogenesis, in adult organ regeneration and in wound healing. In addition, HGF exerts protective effects on epithelial and non-epithelial organs (including the heart and brain) via anti-apoptotic and anti-inflammatory signals. The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 2, 3 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Furthermore, this report also reviews key players involved in Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Driven by data built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

- The report provides a snapshot of the global therapeutic landscape for Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen)

- The report reviews Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) targeted therapeutics and enlists all their major and minor projects

- The report assesses Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

For more information Visit at: http://www.marketresearchreports.com/global-markets-direct/hepatocyte-growth-factor-hepatopoietin-or-lung-fibroblast-derived-mitogen

Related Reports:

Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) - Pipeline Review, H1 2016; visit at - http://www.marketresearchreports.com/global-markets-direct/tumor-necrosis-factor-receptor-superfamily-member-5-b-cell-surface-antigen

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4) - Pipeline Review, H1 2016; visit at - http://www.marketresearchreports.com/global-markets-direct/tumor-necrosis-factor-receptor-superfamily-member-4-act35-antigen-or-tax

About Market Research Reports, Inc.
Market Research Reports, Inc. is the world's leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

Yearly/Quarterly Report Subscription: http://www.marketresearchreports.com/subscriptions